We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.04% | 1,334.50 | 1,333.50 | 1,334.50 | 1,337.50 | 1,333.00 | 1,335.00 | 248,556 | 08:37:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.22 | 55.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
09/12/2022 15:55 | Any reason why it's down over last 2 days | alibizzle | |
09/12/2022 14:42 | It is slightly amusing to think so many whizz kids in US and UK might have gotten caught short in this stock and since the courtroom results, they have to spend their entire time trying to talk it down.... I wonder what bollx they will try to come up with next.😃ԅ | netcurtains | |
09/12/2022 12:29 | I think the message is that what's holding GSK back was never really Zantac, that's just a temporary blip thing. The real problem is their long term poor performance. | anhar | |
09/12/2022 08:42 | Hard to swallow why markets panicked over Zantac It’s too soon to say the great Zantac panic – the one that clobbered GlaxoSmithKline&rsqu | zho | |
09/12/2022 08:21 | 1600 starting to look like a great exit opportunity! | spoole5 | |
08/12/2022 10:49 | From a high of almost £16 yday to £14.70 now , it's the GSK rollercoaster! | alibizzle | |
08/12/2022 10:49 | sold at 1560 when to buy back? or maybe buy WWH instead | phillis | |
08/12/2022 09:38 | ..so, once it sinks in, it looks like it will settle around £16-£17 over the next month or two. £18 once California court 'wins' come through. When should we expect good news from California? | netcurtains | |
08/12/2022 09:37 | Price drop could be due to,speculative,losin | abdullla | |
08/12/2022 09:34 | If there was bad news about Zantac this would go down for days! With good news couldn't hold £15 | mj19 | |
08/12/2022 09:18 | Speculation sells ! | abdullla | |
07/12/2022 20:04 | ..so, once it sinks in, it looks like it will settle around £16-£17 over the next month or two. £18 once California court 'wins' come through. | netcurtains | |
07/12/2022 19:45 | Ah ok it just last night it said up $3 around 10% | alibizzle | |
07/12/2022 19:29 | I think it's just coming off the 16 quid highs we saw over here at 8.00 am and is in line with the UK close. | stewart64 | |
07/12/2022 19:26 | Just says down 3% | alibizzle | |
07/12/2022 19:01 | It opened adjusted for Zantac. 36.86 ÷1.22÷2= about £15.10....No? | stewart64 | |
07/12/2022 18:35 | Down 1 dollar in USA (3%) . Recovery didn't last long ! | alibizzle | |
07/12/2022 18:19 | gsk need a pipeline. Think Zantac has been masking this issue, hence to solid bounce Zantac days Expect £14.50 or lower in the next few trading sessions | pol123 | |
07/12/2022 17:20 | GSK will sadly never have the Magic stardust attached to AZN. I don't get it...their Covid story didn't end well, the first world is totally reliant on Pfizer and Moderna. Pfizer's drugs are better imo, the NHS partially relies on Pfizer for some of the big beasts like statins. AZN trades on a p/e ten times Pfizer. Can someone cleverer than me explain why? | stewart64 | |
07/12/2022 17:03 | I want GSK to have a p/e if 50 that would be nice | mj19 | |
07/12/2022 15:56 | The Zantac claim was only ever going to get to 2 billion,about 3% of Market Cap. I guess the decision also sets a principle for future claims and indeed AZN and Pfizer have risen off the back of this. GSK and Pfizer ( the latter is on a p/e of less than 6 for 2022) look cheap to me anyway. AZN is another story. How you can justify a p/e of 75 over the last 5 years is the biggest mystery to me in the modern history of the FTSE 100. | stewart64 | |
07/12/2022 15:49 | These were £16+ before the Zantac stuffStill a bargain long termAnd GSK is a bid target easily | mj19 | |
07/12/2022 15:45 | Great news. As the analyst note says though, this has mostly removed a negative but we also need to see positives in terms of additions to and solid progress in the pipeline. | rikky72 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions